Analysis of Nuclear Receptor Coactivator 5 (NCOA5) Messenger RNA Expression and rs2903908 Single Nucleotide Polymorphism of NCOA5 in an Egyptian Cohort with Behçet's Disease: A Single-Center Case-control Study

Ocul Immunol Inflamm. 2022 Aug;30(6):1436-1446. doi: 10.1080/09273948.2021.1889610. Epub 2021 Jul 13.

Abstract

The nuclear receptor coactivator 5 (NCOA5) has been linked to several inflammatory disorders, including Behçet's disease (BD). We evaluated the expression of NCOA5 messenger RNA (mRNA) using real-time reverse transcription-polymerase chain reaction, and analyzed the rs2903908 T > C of NCOA5 using TaqMan allelic discrimination assay in 49 Egyptian BD patients and 50 controls. The NCOA5 mRNA levels were higher in patients compared to controls (p = .02), female patients compared to males (p = .037), and in patients with ocular involvement (p = .049). Non-CC genotype carriers had a higher frequency of articular manifestations compared with CC carriers (p = .047). Genotypes CC + CT were associated with reduced risk of cutaneous involvement (OR = 0.27, p = .04). CC carriers with active BD or cutaneous manifestations displayed significantly lower NCOA5 mRNA expression than TT carriers. Our results demonstrate that NCOA5 is linked to BD clinical findings and activity.

Keywords: NCOA5; Ocular Behçet’s disease; mRNA; real-time polymerase chain reaction; rs2903908.

MeSH terms

  • Behcet Syndrome* / diagnosis
  • Behcet Syndrome* / genetics
  • Case-Control Studies
  • Egypt / epidemiology
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Male
  • Nuclear Receptor Coactivators* / genetics
  • Nuclear Receptor Coactivators* / metabolism
  • Polymorphism, Single Nucleotide*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism

Substances

  • Nuclear Receptor Coactivators
  • RNA, Messenger
  • NCOA5 protein, human